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A B S T R A C T
Purpose
Measuring the effect of cancer interventions must take into account rising cancer incidence now
that people live longer because of declines in mortality from cardiovascular disease (CVD). Cancer
mortality rates in the population do not accomplish this objective. We sought a measure that
would reveal the effects of changing mortality rates from other diseases.
Methods
We obtained annual breast, colorectal, lung, and prostate cancer mortality rates from the
Surveillance, Epidemiology, and End Results registries; we obtained noncancer mortality rates
from national death certificates, 1975 to 2005. We used life-table methods to calculate the burden
of cancer mortality as the average person-years of life lost (PYLL) as a result of cancer
(cancer-specific PYLL) and quantify individual—and perhaps offsetting—contributions of the two
factors that affect cancer-specific PYLL: mortality rates as a result of cancer and other-
cause mortality.
Results
Falling cancer mortality rates reduced the burden of mortality from leading cancers, but increasing
cancer incidence as a result of decreasing other-cause mortality rates partially offset this progress.
Between 1985 and 1989 and between 2000 and 2004, the burden of lung cancer in males declined
by 0.1 year of life lost. This decline reflects the sum of two effects: decreasing lung cancer
mortality rates that reduced the average burden of lung cancer mortality by 0.33 years of life lost
and declining other-cause mortality rates that raised it by 0.23 years. Other common cancers
showed similar patterns.
Conclusion
By using a measure that accounts for increased cancer incidence as a result of improvements
in CVD mortality, we find that prior assessments have underestimated the impact of
cancer interventions.
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INTRODUCTION
The 1971 National Cancer Act led to unprecedented
growth in cancer research in the United States1; yet
cancer mortality rates scarcely changed while mor-
tality rates from noncancer diseases steadily de-
clined. Between 1970 and 2008, mortality rates from
heart disease, cerebrovascular disease, and accidents
declined 62%, 73%, and 38%, respectively. In the
same period, cancer mortality rates declined just
12%, mostly since 1990,2,3 which led scholars to
question the return on investments in cancer pre-
vention, screening, and treatment.4-12 Uncertain re-
turns also prompted the National Cancer Institute
(NCI) to convene an extramural committee to eval-
uate population-level measures of progress against
the burden of cancer mortality.13 The Extramural
Committee identified the person-years of life lost as
a result of cancer (cancer PYLL) as a useful measure
of the burden of cancer mortality because it takes
into account both changes in cancer mortality rates
and changes in other-cause mortality rates.
To date, the leading population-level measures
of progress against cancer mortality have been can-
cer survival time and mortality rates. These mea-
sures are ideally suited to assess the direct effect of
prevention, screening, and treatment on the cancer
itself, but they—by construction—neglect changes
in other-cause mortality rates.13-15 The NCI Extra-
mural Committee recommended cancer PYLL aver-
aged across the US adult population to measure
cancer burden.13 Conceptually, cancer PYLL equals
the gain in life expectancy in the absence of deaths
from cancer. Therefore, it directly measures the bur-
den by assessing how many years of life are lost to
cancer at the population level.16 However, cancer
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PYLL has not been well suited for assessing progress over time because
changes in cancer PYLL are confounded by changes in noncancer
mortality rates, a limitation raised by the NCI Extramural Commit-
tee.13 Thus, improvements in cancer PYLL might be offset by increas-
ing incidence of cancer because of decreasing mortality rates from
other causes, which would increase life expectancy and allow more
time for cancer to develop and be diagnosed.
In this study, we use an established demographic method17 that
overcomes the previous limitation in PYLL identified by the NCI
Extramural Committee13 and enables us to quantify individual, and
perhaps offsetting, contributions of the two factors that affect cancer-
specific PYLL: mortality rates as a result of cancer and other-cause
mortality. By measuring direct contributions of cancer mortality rates
on the burden of cancer mortality, we assess the progress of cancer
mortality and changes in its burden since 1985 and examine the pace
of progress by cancer type, race, and sex.
METHODS
Patient Data
We obtained breast, colon and rectum (colorectal cancer [CRC]), lung,
and prostate cancer incidence and mortality data from the NCI’s Surveillance,
Epidemiology, and End Results (SEER) 9 registry database. SEER 9 consists of
tumor registries in Atlanta, GA; Connecticut; Detroit, MI; Hawaii; Iowa; New
Mexico; San Francisco-Oakland, CA; Seattle-Puget Sound, WA; and Utah.
The SEER 9 registries, which cover approximately 10% of the US population,
form the largest, most representative, and longest running national cancer
incidence database. SEER captures virtually all of the cancers occurring in the
geographic areas covered by the SEER registries; a person’s entry into the
registries begins with their diagnosis and ends, if relevant, with their death. All
of the SEER sites use the same version of the International Classification of
Diseases to assign diagnostic codes. Therefore, users of the SEER database can
perform accurate time trend analyses of cancer mortality rates.10,18 We ana-
lyzed 1,605,372 cancer cases diagnosed between 1975 and 2005, included only
the first matching record for each person, and excluded deaths from cancers
identified only by autopsy or death certificate. SEER classifies cancer as the
cause of death on the basis of the death certificate, the identity of a primary
tumor, and relevant comorbidities. We used one further requirement: the
cancer death must have occurred within 10 years of its diagnosis.19,20 For
example, cancer deaths occurring in 1985 must have been diagnosed no earlier
than 1975. By allowing this 10-year time window between diagnosis and death,
we were able to calculate incidence-based mortality rates beginning in 1985 for
1,198,806 incident cancer cases. An incidence-based mortality rate for a spe-
cific cancer equals the number of cancer deaths divided by the total number of
people residing in the geographic areas covered by the SEER registries. We
calculated these mortality rates by cancer type, age group, sex, and calen-
dar year.
To obtain death rates from other causes, we used 1985 to 2005 data from
the National Center for Health Statistics (NCHS) Multiple-Cause-of-Death
Detail Files. We estimated other-cause mortality rates as the difference be-
tween NCHS all-cause mortality rates and SEER incidence-based cancer mor-
tality rates.
Analytic Methods
We assessed progress in reducing the burden of cancer mortality through
changes in the PYLL as a result of cancer.17 Cancer PYLL is estimated as the
difference in life expectancies calculated from two life-tables: life-table 1 was
computed with only other-cause mortality rates and life-table 2 was computed
with both cancer and other-cause mortality rates.16,21,22 A life-table estimates a
population’s life expectancy on the basis of its mortality rates and accounts for
the age distribution of the population by transforming mortality rates into
probabilities of survival.16,23-25 By denominating cancer PYLL on the US adult
population age  40 years, the measure can be evaluated on the same scale as
life expectancy. Thus, we are able to assess progress in reducing the burden of
adult cancer mortality.
We overcome the previous limitations in interpreting time trends in
PYLL (an issue raised by the NCI Extramural Committee) by quantifying
individual contributions of the two factors that affect cancer PYLL: cancer and
other-cause mortality rates.17 We schematically represent our approach in
Figure 1 and fully describe it in the Data Supplement. We performed this
analysis for specific cancers in people age 40 to 84 years over consecutive 5-year
periods beginning with 1985 to 1989 through 2000 to 2004.
Conceptually, cancer PYLL depends on the competing risks of cancer
and noncancer mortality. For example, suppose cancer mortality rates re-
mained constant between times 1 and 2 but noncancer mortality rates declined
(Fig 1A). At time 1, the life expectancy based only on noncancer mortality rates
is higher than the life expectancy based on both noncancer and cancer mortal-
ity rates (Fig 1B). The difference between these life expectancies represents the
PYLL as a result of cancer averaged across the population (cancer PYLL). At
time 2, cancer PYLL is even greater than at time 1 because noncancer mortality
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Fig 1. Changes in the average person-years of life lost (PYLL) depend on changes in mortality rates from both cancer and other causes. (A) Mortality rates for cancer
and other causes at two time points. (B) Life expectancy calculated from cancer and other-cause mortality rates (blue and gold) and life expectancy calculated from
only other-cause mortality rates for time 1 (light blue) and time 2 (light gold). (C) Cancer PYLL equals the difference in life expectancy calculated from only other-cause
mortality rates and life expectancy calculated from cancer plus other-cause mortality rates. (D) Change in cancer PYLL equals the difference between cancer PYLL at
time 2 and cancer PYLL at time 1.
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rates declined over time (Fig 1C). Cancer mortality did not contribute to the
change in cancer PYLL because cancer mortality rates themselves had not
changed. Therefore, decreases in noncancer mortality rates confound the
interpretation of changes in cancer PYLL (Fig 1D). In this example, all of the
increase in cancer PYLL is a result of decreasing noncancer mortality rates. We
do not report any sampling uncertainty in cancer PYLL because our calcula-
tions use registry and vital statistics data that fully capture the mortality expe-
rience of defined populations.25 The Harvard University institutional review
board approved the study.
RESULTS
Average PYLL
To demonstrate the principal results of our investigation, we
used the leading cause of cancer deaths—lung cancer—and consider
changes in the burden of male lung cancer (measured by PYLL) as a
result of changes in lung cancer mortality rates (Fig 2). In 1985, the life
expectancy by using life-tables based only on other-cause mortality
rates was 0.87 years higher than the life expectancy using life-tables
based on both lung cancer and other-cause mortality rates. By the
definition of PYLL, the lung cancer PYLL1985 is 0.87 years (Fig 2A). By
1990, lung cancer PYLL grew to 0.90 years, an increase of 0.03 years. As
shown in the first set of bars in Fig 2B, this growth in PYLL (gold bar)
resulted from the combined effect of decreasing other-cause mortality
rates (blue bar), which raised lung cancer PYLL by 0.07 years, and
decreasing lung cancer mortality rates (gray bar), which lowered PYLL
0.04 years. The pattern of gold bars over time (Fig 2A) shows that the
burden of lung cancer mortality shrank since 1990. This shrinkage was
primarily the result of decreasing lung cancer mortality rates (Fig 2B,
gray bars) that consistently reduced the burden of lung cancer mor-
tality, an effect that was partially offset by decreasing other-cause
mortality rates (blue bars, Fig 2B). Decreasing lung cancer mortality
rates tripled their contribution to reducing the burden of lung cancer
mortality from 0.04 years in 1985 to 1989 to 0.12 years in 2000 to 2004.
Not all of this progress was realized at the population level because
other-cause mortality rates also decreased, and the resulting increase
in life expectancy and consequent change in lung cancer incidence
partially offset this progress.
Time Trends and Decomposition of Average PYLL by
Sex, Race, and Cancer Site
Decreasing cancer mortality rates reduced the burden of specific
cancers, although the timing and magnitude has varied among cancers
and sex (Data Supplement). For females, the burden of lung cancer
mortality grew from 1985 to 1989 and from 1995 to 1999, but in
contrast to the decline in males, it remained nearly constant thereafter.
Although the burden of lung cancer mortality appeared constant,
decreasing lung cancer mortality rates in women actually reduced it,
but this reduction was offset by nearly equal growth in cancer PYLL
from declining other-cause mortality rates. For example, between
2000 and 2004, decreasing lung cancer mortality rates reduced the
burden of lung cancer mortality in women by 0.04 years and declining
other-cause mortality rates raised it by 0.03 years, leading to an overall
0.01 years of reduction in the burden of lung cancer mortality. Other
cancers showed similar patterns. During 1985 to 1989, decreasing
CRC mortality rates for both males and females reduced the burden of
CRC mortality, although this reduction was more consistent for fe-
males than males. Decreases in breast cancer mortality rates consis-
tently reduced the burden of breast cancer mortality from 1985 to
1989 with the greatest reduction occurring from 1995 to 1999. Finally,
most of the reduction in the burden of prostate cancer mortality from
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Fig 2. Male lung cancer average person-years of life lost (PYLL) by year, and its changes and decomposition over 5-year intervals showing large reductions in male
lung cancer burden as a result of declines in lung cancer mortality rates since 1985. (A) Male lung cancer PYLL by year. (B) Decomposition of male lung cancer PYLL
over 5-year intervals. Gold bars indicate the change in PYLL, gray bars indicate the change in PYLL as a result of changes in lung cancer mortality rates, and blue bars
indicate the change in PYLL as a result of changes in other-cause mortality rates. We do not report any sampling uncertainty in PYLL or in the decomposition of PYLL
because our calculations use registry and vital statistics data that fully capture the mortality experience of defined populations. Note that PYLL, the average years of
life lost per US adult, equals the gain in life expectancy in the absence of deaths resulting from cancer.
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rates, with relatively little offsetting contribution from lower other-
cause mortality rates.
Last, we examined patterns in the burden of cancers by sex and
race and found that although the burdens of lung and prostate cancer
mortality shrank more for black than for white males, the burdens of
breast cancer and CRC mortality shrank more consistently for white
than for black females (Data Supplement). For example, between 2000
and 2004, decreasing lung cancer mortality rates reduced the burden
of lung cancer mortality by 0.16 years for black males and 0.12 years for
white males but by only 0.06 years for black females and 0.05 years for
white females.
DISCUSSION
Our methods provide a more accurate means of assessing progress
against the population-level burden of cancer mortality as measured
in average PYLL as a result of cancer. We show that accurately mea-
suring progress depends on changes in mortality rates of both cancer
and other diseases. We estimate how the years of life lost from cancer
are directly affected by cancer mortality itself and indirectly affected by
increased cancer incidence because of greater longevity as a result of
improvements in the prevention, detection, and treatment of
other diseases.
Our study realizes the promise of the conceptual advances made
by the 1990 NCI Extramural Committee. The committee noted an
urgent need for research into how changes in other causes of death
affect cancer statistics.13 The committee found PYLL to be an appeal-
ing measure of progress because it incorporates mortality rates from
both cancer and other diseases. However, the committee identified an
important drawback of using PYLL to assess progress against cancer
over time—PYLL will worsen when other-cause mortality rates de-
cline, even if cancer mortality rates remain constant. To the best of our
knowledge, no subsequent work has addressed this drawback of PYLL.
For the first time, our approach overcomes this problem by quantify-
ing the contribution of changes in mortality rates from cancer and
other diseases to changes in PYLL from cancer. We are now able to
conclude that seemingly stagnant progress against many leading can-
cers (eg, female lung cancer between 1995 and 2005) actually resulted
from offsetting contributions of decreasing cancer mortality rates and
decreasing other-cause mortality rates.
Our study introduces, for the first time, an approach to assessing
both the burden of cancer and progress over time. It has been possible
to measure each of these characteristics individually but not both at
the same time. For example, the prevalence of cancer and years of life
lost as a result of cancer are, in principle, ideal measures of the burden
of cancer mortality because they explicitly consider competing mor-
tality from other causes of death. Relative survival (ie, the ratio of life
expectancy for patients with cancer to life expectancy for cancer-free
individuals) and standardized mortality rates (the weighted sum of
age-specific cancer mortality rates, in which the weights equal the
proportion of the population in each age group) are, in principle, ideal
measures of progress against cancer mortality because they focus ex-
clusively on cancer.10 However, none of these measures assess both the
burden of cancer and progress of this burden over time; changes in the
burden result from changes in cancer mortality rates but are con-
founded by changes in other-cause mortality rates. In contrast, we
used cancer PYLL as a measure of burden and assessed progress
against the burden of cancer mortality over time by quantifying how
much of the change in PYLL is a result of mortality rates from cancer
and from other causes. Our approach accounts for the increase in
cancer prevalence as a result of longer lifetime in which to develop
cancer. In addition, by using life-table methods, our measure accounts
for changes in the proportion of the population by age over time and
therefore allows meaningful comparisons across time and population
subgroups (eg, race/ethnicity).
Our results demonstrate progress against the burden of cancer
mortality, but we show that conventional measures may underesti-
mate this progress because they do not measure the offsetting effects
that result from larger improvements in the mortality of noncancer
diseases.26 By quantifying the contribution of cancer and noncancer
diseases to the burden of cancer mortality, we reveal more accurately
the aggregate contribution of cancer prevention, screening, and treat-
ment on progress against cancer.
Our study has some potential limitations, which may affect its
internal and external validity. First, we required that cancer death
must have occurred within 10 years of diagnosis when calculating
incidence-based mortality rates. This 10-year window ensures that
incidence-based cancer mortality rates are within 10% of cancer death
rates estimated from national death certificate data.19 As screening
became more widespread over time, a larger number of cancers were
diagnosed at the earliest stages and may have resulted in a higher
proportion of indolent cancers that lead to an underestimation of
cancer mortality rates. To address this potential problem, we set a
10-year window to reduce the effect of indolent cancer on cancer
mortality rates. For our sensitivity analysis, we varied the time interval
by 2.5-year increments between 5 and 15 years and reached nearly
identical substantive conclusions regarding the timing and magnitude
of progress against the burden of cancer mortality (Data Supplement).
Second, the SEER registries do not capture the entire US population.
Our results may not be generalizable to the national population to the
extent that the SEER registries fail to represent more general cancer
mortality trends. For example, screening rates for breast and prostate
cancer and CRC may be higher in the SEER registries than in the rest of
the United States, which may result in a higher proportion of indolent
cancers and an underestimation of cancer mortality rates. To address
this potential problem, we conducted additional analysis by using only
national-level mortality data, and we reached similar conclusions
(Data Supplement). Although national-level mortality data capture
the entire US population, they rely on death certificates. We were not
able to ascertain the date of cancer diagnosis from death certificates for
calculating incidence-based mortality rates as we could by using SEER
registry data. Third, our method assumes causes of death to be mutu-
ally independent (ie, cancer death rates are not correlated with non-
cancer death rates) when estimating the contribution of each cancer to
the change in the burden of cancer mortality.17 This assumption may
be reasonable in younger patients with cancer who have fewer comor-
bid conditions but may be more tenuous in older patients when the
prevalence of serious advanced chronic disease is greater and can
shorten cancer survival. We address this assumption by restricting the
age range in our analysis to people age 40 to 84 years for whom the
prevalence of multiple comorbidities is lower than among people age
85 years or older.27 Other methods to assess progress against cancer
mortality relax the mutual independence assumption among causes of
death but, in doing so, invoke untestable assumptions about both the
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competition among multiple causes of death28 and the interrelation-
ship of comorbid diseases and disease progression.29,30
In conclusion, as mortality from cardiovascular disease and other
major diseases continues to decline, the population-level burden of
cancer mortality may grow because life expectancy will increase, lead-
ing to more years of life for cancer to develop and be diagnosed. Our
framework suggests that the average age of cancer diagnosis increases
as the exposure to cancer lengthens; this pattern has been empirically
observed for many leading cancers.31 Given the decline in noncancer
mortality rates, assessing the direct contribution of cancer mortality
rates on the burden of cancer mortality requires new methodologies
that distinguish the effects of cancer care from the effects of medical
care that reduce mortality from other diseases. We show that the
average PYLL resulting from cancer is a useful metric of the burden of
cancer mortality because it jointly considers changes in cancer and
other-cause mortality rates and is denominated on the population as a
whole. By decomposing changes in the average PYLL as a result of
cancer over time, we are then able to assess the contribution of cancer-
specific mortality rates on changes in the burden of cancer mortality,
adjusting for progress in reducing other causes of death. In doing so,
we find sustained progress since the years from 1985 to 1989 in reduc-
ing the population-level burden of cancer mortality.
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